Quarterly ResultMay 13, 2026, 04:12 PM
Aytu BioPharma Reports Q3 FY26 Net Loss of $5.6M; EXXUA Revenue $2.4M
AI Summary
Aytu BioPharma reported a net loss of $5.6 million for fiscal Q3 2026, a significant decline from a net income of $4.0 million in the prior year. Total net revenue decreased to $12.4 million from $18.5 million year-over-year. The company's new product, EXXUA, generated $2.4 million in net revenue despite a partial quarter of full sales force support, showing encouraging initial traction. This performance reflects strategic investments in EXXUA's launch and a shift in sales force focus, which impacted legacy ADHD and Pediatric portfolio revenues.
Key Highlights
- Net loss was $5.6 million in Q3 FY26, compared to net income of $4.0 million in Q3 FY25.
- Total net revenue decreased to $12.4 million in Q3 FY26 from $18.5 million in Q3 FY25.
- EXXUA net revenue was $2.4 million in Q3 FY26, with over 1,300 prescriptions written.
- Adjusted EBITDA was $(2.8) million in Q3 FY26, down from $3.9 million in Q3 FY25.
- ADHD Portfolio net revenue fell to $9.1 million from $15.4 million year-over-year.
- Pediatric Portfolio net revenue decreased to $0.9 million from $3.1 million year-over-year.
- Cash and cash equivalents stood at $26.7 million as of March 31, 2026.
- Stockholders' equity increased to $35.1 million due to warrant reclassification.